Vaxart (VXRT) Price & Analysis

Compare

4,379 Followers

VXRT Stock Chart & Stats

$0.36

-$0.02(-2.57%)

At close: Jan 08 4:00 PM EST

$0.36

-$0.02(-2.57%)

Day’s Range― - ―

52-Week Range$0.26 - $0.98

Previous CloseN/A

Volume1.40M

Average Volume (3M)573.73K

Market Cap

$87.63M

Enterprise Value$73.69M

Total Cash (Recent Filing)$28.79M

Total Debt (Recent Filing)$15.44M

Price to Earnings (P/E)―

Beta1.90

Next Earnings

Mar 19, 2026

EPS Estimate

-0.05

Last Dividend Ex-Date

Nov 09, 2012

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding240,069,840

10 Day Avg. Volume484,123

30 Day Avg. Volume573,734

Financial Highlights & Ratios

PEG Ratio0.27

Price to Book (P/B)5.48

Price to Sales (P/S)11.24

P/FCF Ratio-7.12

Enterprise Value/Market Cap0.84

Enterprise Value/Revenue0.50

Enterprise Value/Gross Profit0.50

Enterprise Value/Ebitda-1.92

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.26

Revenue Forecast (FY)$141.30M

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.

Growth PotentialVaxart's efforts to refine its norovirus program address a significant unmet need in a market with no approved vaccines, showcasing potential for growth and innovation.

Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.

Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.

Bears Say

Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.

Vaxart News

Vaxart’s Earnings Call: Dynavax Partnership and Revenue Surge

Vaxart (($VXRT)) has held its Q3 earnings call. Read on for the main highlights of the call. Vaxart’s...

29d ago

VXRT

Vaxart’s Strategic Moves and Financial Highlights

Vaxart ( ($VXRT) ) has released its Q3 earnings. Here is a breakdown of the information Vaxart presented...

1M ago

VXRT

Options Volatility and Implied Earnings Moves Today, November 13, 2025

Today, several major companies are expected to report earnings: Applied Materials (AMAT), Ballard Power Systems (BLDP), Walt Disney...

1M ago

Is VXRT a Buy, Before Earnings?

Vaxart (VXRT) is scheduled to report 3rd quarter earnings on 11/13/2025, after the market closes. Regarding Q3 estimates,...

1M ago

VXRT

Vaxart Partners with Dynavax for Oral COVID-19 Vaccine

Vaxart ( ($VXRT) ) has shared an announcement. On November 4, 2025, Vaxart entered into an exclusive license...

1M ago

VXRT

Dynavax enters license agreement for Vaxart’s oral COVID-19 vaccine program Vaxart

Dynavax Technologies (DVAX) and Vaxart (VXRT) announced that they have entered into an exclusive, worldwide license and collaboration...

1M ago

DVAX

VXRT

Vaxart Secures Funding for COVID-19 Trial

Vaxart ( ($VXRT) ) just unveiled an announcement. On August 5, 2025, Vaxart received a stop work order...

2M ago

VXRT

Vaxart Faces Nasdaq Delisting, Moves to OTCQX

The latest update is out from Vaxart ( ($VXRT) ). Vaxart, Inc. faced a delisting from Nasdaq after...

3M ago

VXRT

Vaxart wthdraws reverse stock split proposal

Vaxart (VXRT) has withdrawn its reverse stock split proposal. “After careful consideration, we have decided to officially withdraw...

3M ago

VXRT

Vaxart Withdraws Proposal, Cancels Stockholder Meeting

An announcement from Vaxart ( ($VXRT) ) is now available. Vaxart, Inc. had planned a special meeting of...

3M ago

VXRT

Vaxart shareholders reiterate intent to vote against reverse stock split

Richard John Burgess, Daniel Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Mark Silverberg, Matthew...

3M ago

VXRT

Vaxart shareholders ‘condemn’ board decision to adjourn reverse stock split vote

Richard John Burgess, Daniel Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew Wallace, and...

3M ago

VXRT

Vaxart Adjourns Stockholder Meeting for Vote Solicitation

Vaxart ( ($VXRT) ) has shared an update. On September 5, 2025, Vaxart, Inc. adjourned its special meeting...

3M ago

VXRT

Vaxart announces adjournment of special meeting of stockholders

Vaxart (VXRT), announced that its 2025 special meeting of stockholders has been adjourned to Friday, September 19, 2025...

3M ago

VXRT

VXRT FAQ

What was Vaxart’s price range in the past 12 months?

Vaxart lowest stock price was $0.26 and its highest was $0.98 in the past 12 months.

What is Vaxart’s market cap?

Vaxart’s market cap is $87.63M.

When is Vaxart’s upcoming earnings report date?

Vaxart’s upcoming earnings report date is Mar 19, 2026 which is in 95 days.

How were Vaxart’s earnings last quarter?

Vaxart released its earnings results on Nov 13, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.03.

Is Vaxart overvalued?

According to Wall Street analysts Vaxart’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vaxart pay dividends?

Vaxart pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart dividends here

What is Vaxart’s EPS estimate?

Vaxart’s EPS estimate is -0.05.

How many shares outstanding does Vaxart have?

Vaxart has 240,069,840 shares outstanding.

What happened to Vaxart’s price movement after its last earnings report?

Vaxart reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went up 11.111%.

Which hedge fund is a major shareholder of Vaxart?

Currently, no hedge funds are holding shares in VXRT

Vaxart Stock Smart Score

Neutral

Fundamentals

Return on Equity

-106.52%

Trailing 12-Months

Asset Growth

25.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vaxart

Vaxart, Inc. is a biotechnology company focused on developing oral vaccines based on its proprietary Vaxart platform. The company operates primarily in the biotechnology sector and is engaged in the research, development, and commercialization of oral vaccine candidates for various infectious diseases, including influenza and norovirus. Vaxart's innovative approach utilizes a tablet-based vaccine delivery system, aiming to enhance patient compliance and broaden immunization accessibility.

Vaxart (VXRT) Earnings & Revenues

Historic Earnings Reports

VXRT Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted a significant partnership with Dynavax, which boosts financial stability and validates Vaxart's technology. Positive developments in the norovirus program and increased revenue are notable. However, the stop work order from BARDA and delays in norovirus trials present challenges.View all VXRT earnings summaries